A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)

Conditions:   Ovarian Neoplasms;   Endometrial Neoplasms;   Uterine Cervical Neoplasms;   Vulvar Cancer;   Vagina Neoplasm;   Clear Cell Carcinoma Interventions:   Drug: Dostarlimab;   Drug: Bevacizumab;   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Paclitaxel Sponsor:   Yonsei University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials